Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most statements about tachycardia/palpitations, mechanism, evaluation workup, and management are not supported by the provided LYRICA prescribing information excerpts. Some safety-related statements (tapering/discontinuation) align with the label, but overall label alignment is weak due to multiple unsupported or label-unaddressed assertions.
Category Scores
Accurate Statements
Pregabalin should not be stopped abruptly without medical advice because abrupt changes can cause withdrawal-type symptoms.
Label Section 2 (discontinue: taper gradually over minimum of 1 week) and Section 5.6 (withdraw gradually; after abrupt/rapid discontinuation, symptoms reported including insomnia, nausea, headache, anxiety, hyperhidrosis, and diarrhea).
Pregabalin dose-related effects or starting/restarting pregabalin can cause symptoms soon after starting or increasing the dose.
Label Section 5.2 (hypersensitivity reported shortly after initiation) and Section 5.6 (symptoms after abrupt/rapid discontinuation).
Unsupported Statements
Pregabalin can cause side effects that may feel cardiac, such as dizziness or changes in balance.
The provided label excerpt supports dizziness and somnolence as adverse effects, but does not link them to 'cardiac' sensations or 'changes in balance' (balance specifically not supported in provided excerpts).
A true drug-related tachycardia from pregabalin is less common than more typical side effects like dizziness, sleepiness, or swelling.
The provided excerpts do not address tachycardia frequency or relative frequency versus dizziness/somnolence/peripheral edema.
If tachycardia occurs while taking pregabalin, it can be triggered indirectly (for example, if pregabalin causes dizziness and anxiety or worsens an underlying condition).
The provided excerpts do not discuss tachycardia causality pathways (direct or indirect) for pregabalin.
Fast heart rate with chest pain, shortness of breath, fainting, severe dizziness, or signs of an allergic reaction ... requires urgent care or emergency evaluation.
The provided label excerpts do not provide guidance that tachycardia with these symptoms requires urgent/emergency evaluation.
Drug interactions that combine pregabalin with other medicines that affect heart rhythm or blood pressure can increase the risk of tachycardia.
The provided label excerpt states PK interactions are unlikely (no significant PK interactions expected); it does not describe increased tachycardia risk from rhythm/BP-affecting medicines.
Dehydration or electrolyte issues can contribute to tachycardia independent of pregabalin.
The provided excerpts do not connect dehydration/electrolyte issues to tachycardia in the context of pregabalin.
Underlying conditions such as anxiety, thyroid disease, infection/fever, anemia, and heart rhythm disorders can worsen regardless of pregabalin.
The provided excerpts do not mention these conditions in relation to tachycardia in patients taking pregabalin.
Withdrawal or abrupt changes in nervous-system medications can cause rebound symptoms including palpitations.
Section 5.6 lists symptoms after abrupt/rapid discontinuation (insomnia, nausea, headache, anxiety, hyperhidrosis, diarrhea) but does not mention palpitations.
Pregabalin withdrawal is more typically associated with other withdrawal effects rather than palpitations.
The provided excerpts do not characterize palpitations as absent/less typical in pregabalin withdrawal.
Clinicians often check vital signs and assess for symptoms and risk factors if tachycardia happens after starting pregabalin or after a dose increase.
The provided excerpts do not describe evaluation practices for tachycardia in relation to pregabalin initiation/dose increase.
Clinicians often review other medications and substances, including stimulants, when tachycardia occurs in a patient taking pregabalin.
The provided excerpts do not mention tachycardia evaluation or stimulants in this context.
Clinicians may consider slower titration or dose reduction or switching to another therapy depending on the cause and severity of tachycardia.
The provided excerpts do not provide treatment adjustment or switching guidance for tachycardia.
Doctors evaluating tachycardia in a patient taking pregabalin may measure heart rate and blood pressure repeatedly, including standing/sitting measurements if dizziness is present.
No such diagnostic/orthostatic measurement guidance is included in the provided excerpts.
Doctors evaluating tachycardia in a patient taking pregabalin may obtain an ECG to look for arrhythmia.
ECG guidance is not included in the provided excerpts.
Doctors evaluating tachycardia in a patient taking pregabalin may order labs when indicated, such as thyroid function tests, electrolyte tests, and blood counts, especially if symptoms persist.
No such lab-work guidance is included in the provided excerpts.
If pregabalin is linked to troubling palpitations/tachycardia and the reaction is consistent and reproducible, clinicians may consider switching to a different neuropathic pain or nerve-related regimen.
The provided excerpts do not discuss switching therapies due to tachycardia/palpitations.
Underlying conditions such as ... can worsen regardless of pregabalin.
The provided excerpts do not state or imply tachycardia worsening due to comorbid conditions in patients taking pregabalin.
Contradictions
Low
AI Statement
Withdrawal or abrupt changes ... can cause rebound symptoms including palpitations.
Label Reference
Section 5.6 provided excerpt lists specific symptoms after abrupt/rapid discontinuation (insomnia, nausea, headache, anxiety, hyperhidrosis, diarrhea) and does not include palpitations; however, this is not a direct direct contradiction, so it is treated as unsupported rather than contradictory.
Important Omissions
No label-supported tachycardia/palpitations-specific warning, adverse reaction, or evaluation/management pathway is included in the provided excerpts; therefore, any claim implying tachycardia is a known pregabalin adverse reaction is an omission of label basis.
Importance:
Moderate
The provided label excerpts emphasize serious hypersensitivity/angioedema symptoms requiring immediate discontinuation (e.g., face/mouth/neck swelling, respiratory compromise). The AI text instead gives urgent/emergency framing for tachycardia/chest pain/SOB without tying to the label’s hypersensitivity/angioedema discontinuation criteria.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements could mislead by presenting tachycardia/palpitations as a pregabalin-related concern with specific causal pathways and evaluation steps that are not supported by the provided label excerpts. One aspect (gradual taper to avoid discontinuation symptoms) is aligned with the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple claims regarding tachycardia/palpitations causation, frequency, drug-interaction risk for tachycardia, and diagnostic/management steps are not supported by the provided prescribing information excerpts.
Suggested Improvement
Restrict claims to label-supported adverse effects and discontinuation guidance. If discussing serious events, align specifically to label sections provided (e.g., dizziness/somnolence; hypersensitivity/angioedema symptoms requiring immediate discontinuation; gradual taper over minimum 1 week on discontinuation). Avoid asserting tachycardia/palpitations as pregabalin-related, or provide only statements that directly match the label excerpts.